Reneuron Share Discussion Threads

[whatno] 04/1/2022 13:41

This from 2015 is informative about the RP trial

[bradders51] 04/1/2022 07:39

Terminator. Are you invested here?

[terminator101] 03/1/2022 16:49

6 months after I highlighted the pedestrian scientists running this outfit making little commercial progress the share price is almost 50% lower. They are still burning shareholders cash at a rate of more than £10 million a year, so the only inevitable thing here is the need for even more cash. This lot have been spending other people's money ever since they took Woodford's coin and did very little with it. Money "invested" here is dead money IMO.

[pdt] 22/12/2021 17:53

And on the other Forum there is an interesting link to a interview that suggests there maybe some BBC reporting of the RP trial in the New Year. Thanks to grizzlyB. It is mentioned about 13 mins in and people being interviewed are the Oxford lead Prof MacLaren and patients. Given that the first person was dosed in October they may be at the 3 month stage.

[pdt] 22/12/2021 15:29

Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree



The total value of the deal is $1.5 billion. Makes Reneuron at market cap of £50m look like a steal.

[terminator101] 17/12/2021 13:56

Seems there is just no keeping this dog up huh

[pdt] 15/12/2021 16:58

I had a top up today, probably my final buy. I really don't like catching a falling knife but the prospects look good to me.

What is likely to happen over the next 12 months ...

Exosomes - they have 7 collaborations and will probably start more over the next year. I also expect at least one deal to be announced from those. Codiak is currently valued at about £200m with two phase 1 exosome trials I believe. So say this part of Rene is worth £50m in 12 months time.

RP - they have already said the results at 1m dose are sufficiently good to move ahead on but they will have the 2m dose data to release in March/April 2022. That will determine the route ahead and I would expect a licence deal in late 2022 to progress to Phase 3. Value to Rene on a licence deal say £150m

Cash - they have sufficient to see them through 2022.

Fosun - more progress on RP/CTX during 2022.

So overall in 12 months I can see the market cap reaching £200m this time next year. That is four times today's cap and a share price of around 300p. Just my back of an envelope musings but it will be interesting to look at this post in a years time to see how wrong I am!

[dickbush] 14/12/2021 09:55

Nice one, small crow.

I've been in this one, trading in and out, for a long time, and it is currently performing as it has many times in the past: after positive news has driven the share price up, further consideration leads to its consistently ticking down as the cash is spent.

Having said that, I do think the current business model and the Chief Scientific Officer are the best I've seen.

[small crow] 11/12/2021 00:07

I'm holding but ..... Here comes my nineteenth nervous breakdown.

[bradders51] 10/12/2021 19:19

"Time is NOT on your side" would not have made a Rolling Stones hit. But "Time IS on your side" did.
One for the baby boomers :-))
Keep the faith in Rene.

[whatno] 10/12/2021 14:11

You certainly can't accuse them of being in a rush :-) I fully expect further delays in the RP trial due to "Omicron". Olav wouldn't say how many more patients had been treated in the Phase 2a extension study on the last call so I suspect it was not good.

A partner will want to see 12 months of data to establish the longevity of the effect of retinal implanted hRPCs at 2million cells dose. As you rightly point out, you can't rush a clinical trial. Rene have data for only 7 people in their PH2a trial according to the latest investor presentation which is a ridiculously low number.

JCyte will have likely completed enrollment in their hRPC phase 3 by the end 2022. They will be several years ahead and might secure 7-year market exclusivity with orphan designation.

Time is not on your side.

[bg23] 10/12/2021 13:28

its very naïve to assume you can rush a medical trial and equally so to assume that you are going to get the best investor result ahead of properly considered trial results.

There are plenty of potential partners waiting in line to look at the results of the various trials as they mature. The better the results, the more likely an 'auction' for rights or ongoing investigation.

time is on our side.

[jpuff] 09/12/2021 15:52

Yep, we need some new and motivated management who consider shareholders not just their own salaries.

[onceaday] 02/12/2021 11:33

RENE are too slow in completing trials to have success with RP. In the last year, jCyte have completed a phase 2b (12 month data) hRPC trial and another phase 2 (NCT04604899) testing repeat dosing. This sets them up nicely for a phase 3 next year for which they already have funding. Sub-retinal delivery MIGHT provide superior results to intravitreal but IV can be administeted by a regular eye doctor in-office rather than a highly skilled surgeon - something which is commercially attractive and will gain market share quickly. We all know the quality.vs marketing story of VHS vs Betamax...

Those holding out hope of a hRPC licensing deal should bear in mind that if its not an attractive enough proposition to develop in-house then they may struggle to offload. Just look at CTX.... There is also regulatory risk - it's not clear whether orphan designation would exclude all other hRPC RP competition (for 7 years.) upon approval of the first hRPC product to market.

[dickbush] 02/12/2021 10:25

If the RP trial results are consistent with the first, they will have a need for big bucks if they can get FDA permission to jump to a Phase 3 trial. Only my guess, but if the results allow that jump, I would expect big bucks to become available from a much larger company, a JV,perhaps. Having said that, if RENE's exosome research is leading edge, as described in the presentation, why wouldn't a larger company just take it over? Hedging again, though, it is hardly unknown for success in Phase 2 to be followed by failure in Phase 3.

[bradders51] 02/12/2021 09:38

Do you reckon they'll sell off/license all RP side and become "just" an exosome company?
More money in that side of the business probably ????

[dickbush] 01/12/2021 16:05

A very positive presentation. I'm disappointed with the lack of share price improvement following it. The company's record of burning through cash without producing a marketable product or research so attractive that bigger companies want to buy it? Having said that, it won't be long to wait for the initial results from the extended RP trial, and exosomes may provide a reasonably soft landing if the results disappoint.

[xow98] 30/11/2021 10:44

Profitability at this stage not an issue, cash flow and progress on trials are the main drivers at this stage.

Net cash utilized by operating activities would appear to have decreased by 0.9m from 2020 (2.6m + 2.9m R&D credit).

When will the most recent R&D tax credit be received?

[zho] 30/11/2021 09:49

#RENE market will eventually value this properly. In the meantime hold the shares tightly. Nice to see they still have £17m in cash.

Exosomes ‘become a market leader’ ‘we are in the right place, at the right time, with the right technology’

[dickbush] 30/11/2021 07:57

"Increased net cash used in operating activities of GBP4.6 million (H1 2020: GBP2.6 million) with H1 2020 benefitting from a GBP2.9m R&D tax credit receipt

- Cash, cash equivalents and bank deposits at 30 September 2021 of GBP17.4 million (31 March 2021: GBP22.2 million) providing at least a 12-month runway."

"...early data from the (RP) extension study expected in late Q1 2022."

[dickbush] 29/11/2021 12:19

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2021 and business update on Tuesday 30 November 2021.

Let's hope the business update gives us something positive.

[small crow] 22/11/2021 09:59

Strange price action early doors with someone dropping £100,000 in what appear to be buys at odd prices. Any ideas?

[whatno] 19/11/2021 12:45

The days of aim biotechs releasing pre-clinical research notes that result in a 30% price spike is long gone. Investors have a much more risk-off approach nowadays and they want to see significant commercial news that affects the bottom line.

[bradders51] 19/11/2021 12:07

Proactive :